Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
NCT00195325
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumors
Neoplasms
Interventions
DRUG:
TTI-237
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer